Brody’s Human Pharmacology 6th Edition Wecker Test Bank

Brody’s Human Pharmacology 6th Edition Wecker Test
Bank


CCS drugs (cell-cycle specific) - ANSWERAnticancer drugs that are:
--> Phase-specific
--> Higher selective toxicity.
--> More likely to be in-cycle
--> Attack only cells that are actively growing and dividing

CCNS drugs (cell-cycle non-specific) - ANSWER--> Anticancer drugs that can
sterilize tumor cells regardless of whether they are cycling or resting in G0 Phase
--> Less-selective toxicity and cause damage to healthy cells.
--> More damage to healthy cells

N for non-proliferating, normal cells,

_____ drugs are used for recruitment and induce non-proliferating clonogenic
fraction to enter into cell cycle - ANSWERCCNS --> Causes increased vulnerability
to CCS agents afterwards since cells are actively dividing.

Adverse effects of CCS drugs - ANSWERThe most rapidly proliferating normal cells
are likely to suffer toxicity along with the tumor cells, but the damage is mostly
reversible

--> Bone marrow resumes production
--> Hair regrows,
--> gut and oral mucosa recover.

Abortion and infertility are irreversible.

Broad adverse effects - ANSWERCCNS drugs

Cisplastin - ANSWERSide effects: Vomiting, nephrotoxicity

Doxorubicin

I <3 rubics cubes - ANSWERSide effects: Cardiotoxicity

Dexrazoxane: Limits toxicity

Vincristine

Crest = the periphery - ANSWERSide effects: Peripheral neuropathy

Bleomycin - ANSWERPulmonary fibrosis

, Surgical debulking - ANSWERA form of selective toxicity, that allows for large portion
of tumor cells to re-enter cell cycle and proliferate, thus causing death.
Clenogenic fraction (non-growing or non-dividing) are unaffected.

Radiation and cell-cycle non-specific cytotoxic drugs are more broad and cause
MORE COLLATERAL DAMAGE.

Oncolytic viral therapy - ANSWEROne that preferentially infects and kills cancer
cells.

Selectively infects lyses only in primary and metastatic cells of that type (eg multiple
myeloma)

Multimodal therapy - ANSWERChemotherapy, radiation, surgery

Selective toxicity - ANSWERSelectively eradicate neoplastic cells without damaging
host (normal) cells.

CCS are more selectively toxic, but they cannot kill clonogenic fraction cells like
CCNS agents.

CCNS agents are used for recruitment (to induce non-proliferating clonogenic
fraction to cycle)

CCS+CCNS deplete growth fraction as recruited

Clonogenic fraction - ANSWERG0 cells (undividing). Targeted by CCNS drugs

Cytotoxic kinetics - ANSWERCancer cells grow exponentially and cancer chemo
uses highest tolerated dose REGARDLESS OF TUMOR SIZE.

Rate killed is logarithmic (first-order kinetics) therefore 3-log dose will decrease
cancer cell population by 3 orders.

The intensity required to reduce a large tumor and a small tumor to half their size is...
- ANSWERTHE SAME

Curative - ANSWERTries to cure cancer. Toxicity is acceptable

Palliative - ANSWERTries to reduce tumor burden to improve disease-related
suffering. Toxicity is unacceptable.

Induction (neoadjuvant) phase - ANSWERINITITAL REGIMEN. STEP 1!!!
Decrease tumor burden by recruiting clonogenic cells into growth fraction. Occurs
prior to tx with other modalities

Intensification phase - ANSWERSTEP 2!!!

Achieve remission by adding more drugs to regimen, increasing dosage, increasing
duration.